테고사이언스
191420KOSDAQ41.3 / 100
Reference Date: 2026-09-08
Company InformationBased on 2025 Annual Report
Business Overview
Tegos Science specializes in developing and producing cell therapy products using advanced cell culture technology, alongside offering contract manufacturing, consulting, and quality management services. The company has commercialized a 3D cultured skin model, NeoDerm®, for animal alternative testing and drug screening. The global cell therapy market is projected to grow from $4.2 billion in 2023 to $7.8 billion by 2028, with Tegos holding three approved cell therapy products in South Korea, including treatments for burns, diabetic foot ulcers, and wrinkle improvement.
Number of Employees
40people
Average Salary
48.0M KRW
Score Calculation Basis
Detailed Financial Score
Higher than industry avg (caution)
Well below industry avg
Half of industry avg (excellent)
Avg ▼12.6% (2-year basis)
Avg ▼93.1% (2-year basis)
Avg ROE -4.0% (declining, 3yr)
Detailed News Sentiment
- Negative테고사이언스, 상반기 매출 8% ↑…R&D 확대로 영업손실 30억
Despite revenue growth, increased R&D expenses led to a significant operating loss.
Detailed Momentum
Near 52w low (14%, downtrend)
1m +13.38% (rising)
Volume dry-up
Detailed Disclosure
- Neutral임원ㆍ주요주주특정증권등거래계획보고서2026-08-18
- Neutral반기보고서 (2026.06)2026-08-14
